Literature DB >> 25277350

Screening breast magnetic resonance imaging in women with atypia or lobular carcinoma in situ.

Theresa Schwartz1, Amy Cyr2, Julie Margenthaler2.   

Abstract

BACKGROUND: Atypical lesions and lobular carcinoma in situ (LCIS) are associated with an increased risk of breast malignancy. The utility of breast magnetic resonance imaging (MRI) screening in this cohort of women after excision of a high-risk lesion has not been previously established. The objective of this study was to investigate outcomes of breast MRI surveillance in this subgroup of high-risk patients.
MATERIALS AND METHODS: We performed a retrospective review of women who required excision of an atypical lesion or LCIS who underwent at least one screening breast MRI from April 2005-December 2011. We collected information on demographics, number of second-look imaging studies recommended, number of biopsies performed and pathologic outcomes.
RESULTS: A total of 179 patients met the inclusion criteria, including 131 (73%) with atypical lesions and 48 (27%) with LCIS. Second-look imaging was recommended for 31 of 131 (23.7%) patients with atypical lesions and 8 of 48 (16.7%) with LCIS. Ten biopsies were performed in the atypical cohort (7.6%) with two revealing a malignancy (Positive Predictive Value [PPV] of 20%). In the LCIS cohort, five biopsies were performed (10.4%) with one revealing a malignancy (PPV of 20%).
CONCLUSIONS: The benefit of breast MRI surveillance in patients after excision of atypical lesions or LCIS has not been clearly delineated previously. Our data demonstrate that the use of screening breast MRI in this cohort results in additional work-up in one-fifth of patients, but a PPV of only 20%. Large, prospective studies would be needed to determine whether breast cancer outcomes differ between patients undergoing conventional breast screening and those undergoing conventional breast screening plus breast MRI surveillance.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical ductal hyperplasia; Atypical lobular hyperplasia; Atypical proliferative lesions; Breast; Breast cancer screening; High-risk breast lesions; Lobular carcinoma in situ; Magnetic resonance imaging

Mesh:

Year:  2014        PMID: 25277350     DOI: 10.1016/j.jss.2014.08.059

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

Review 1.  Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-11-01

Review 2.  Screening MRI in Women at Intermediate Breast Cancer Risk: An Update of the Recent Literature.

Authors:  Manisha Bahl
Journal:  J Breast Imaging       Date:  2022-05-08

3.  Utilization of breast cancer screening with magnetic resonance imaging in community practice.

Authors:  Deirdre A Hill; Jennifer S Haas; Robert Wellman; Rebecca A Hubbard; Christoph I Lee; Jennifer Alford-Teaster; Karen J Wernli; Louise M Henderson; Natasha K Stout; Anna N A Tosteson; Karla Kerlikowske; Tracy Onega
Journal:  J Gen Intern Med       Date:  2017-12-06       Impact factor: 5.128

4.  Lobular carcinoma in situ of the breast - correlation between minimally invasive biopsy and final pathology.

Authors:  Bartłomiej Szynglarewicz; Piotr Kasprzak; Agnieszka Hałoń; Rafał Matkowski
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

Review 5.  Contrast-enhanced MRI for breast cancer screening.

Authors:  Ritse M Mann; Christiane K Kuhl; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2019-01-18       Impact factor: 4.813

6.  Role of Magnetic Resonance Imaging in the Preoperative Staging and Work-Up of Patients Affected by Invasive Lobular Carcinoma or Invasive Ductolobular Carcinoma.

Authors:  Valeria Selvi; Jacopo Nori; Icro Meattini; Giulio Francolini; Noemi Morelli; Diego De Benedetto; Giulia Bicchierai; Federica Di Naro; Maninderpal Kaur Gill; Lorenzo Orzalesi; Luis Sanchez; Tommaso Susini; Simonetta Bianchi; Lorenzo Livi; Vittorio Miele
Journal:  Biomed Res Int       Date:  2018-06-26       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.